III - Information Services Group, Inc. 0 WATCHERS

Why didn't they add MSTR then I'd honestly feel better with Saylor Moon in the index than Fraud III and Fraud II

Neat. Meanwhile, the Artemis III crewed moon landing keeps getting pushed back, to the point where we'll be neck-and-neck with China's moon mission in 2030. They keep meeting all their launch deadlines while the US is busy with our insipid corporate drama. At this rate, they're going to beat us …

GT-02287 addresses multiple potential sources of Parkinson's ($GANX) What’s the first domino in Parkinson’s disease? **Mainstream science points to the lysosome and α-synuclein aggregation—the idea that misfolded α-syn builds up because the lysosomal “trash system” breaks down. But what if that’s not where the problem starts?** The recent Neuroscience poster …

Act III of the AI bubble story arc is underway. Act IV will not be as pleasant.

3i Group: III.L The leading FTSE 100 private equity company 3I group (III.L) is currently trading at close to its NAV value, closing at 2,999p today. It is down around 30% off its peak due to softening demand of like-for-like sales in France, impacting their largest holding: Action, a big …

Gain Therapeutics ($GANX) — quietly emerging as one of the most compelling Parkinson’s stories in biotech. **The set-up that Gain Therapeutics has right now is extremely rare, IMO. Largely de-risked, and is only a week or two away from releasing what is likely some of the most compelling evidence of …

$SHFS Market Cap: \~$4.5M Low float high alpha rocket with a chart that screams multi bagger. Technicals: RSI <30 (deeply oversold), bouncing off 52-week lows, low float = explosive potential. Business: Huge moat and specialty play. The #1 compliant banking/fintech for cannabis. Provides checking, loans, cash management, and compliance tools …

Anyone elsze got a problem where they get into a hobby, buy a bunch of cool shit for said hobby, and then lose interest in the hobby? Looking around this room: -Panasonic GH5/Olympus PEN EP-5/Olympus OM-D EM-10 MK III camera bodies and thousands in Micro Four-Thirds lenses: Haven't taken a …

$SHFS SHFS: Low-Float Powder Keg with 2025 Catalysts Lined Up SHF Holdings (NASDAQ: SHFS), operating as Safe Harbor Financial, is the dominant compliant banking and fintech platform for U.S. cannabis. Low float (under 3.5 million shares free trading) and a proven history of violent upside spikes (multiple 100%+ percent moves …

Keeping a lookout for RVPH. Phase III clinical trial almost completed, mid-late December could have news on FDA approval. Reminds me of SCNX and INTS.

SHFS is your next big bucks maker ROCKET FUEL DD: $SHFS Price: $1.40 Market Cap: ~$4.5M Low float high alpha rocket with a chart that screams multi bagger. Technicals: RSI <30 (deeply oversold), bouncing off 52-week lows, low float = explosive potential. Business: Huge moat and specialty play. The #1 …

$SHFS ROCKET FUEL DD: $SHFS Price: $1.40 Market Cap: ~$4.5M Low float high alpha rocket with a chart that screams multi bagger. Technicals: RSI <30 (deeply oversold), bouncing off 52-week lows, low float = explosive potential. Business: Huge moat and specialty play. The #1 compliant banking/fintech for cannabis. Provides checking, …

DFLI, my DD, risk assessment and investment plan. # DFLI: Deep Dive into My High-Conviction Lithium Battery Play (Bullish/Risky) I've plugged my post into Gemini for a more easily read format and included a fact check at the end of it. I'm a single dad so I use this as …

On the Verge of a Major Announcement… All Signals Point to a Potential Breakout Waiting for a deal... or a major breakthrough. This company isn't relying on just one catalyst; it actually has a whole host of catalysts that could be game-changers for a small biotech company: • Phase III …

(vii) Half Life III

Newron Pharmaceuticals- Again Up 12% - more to come🚀🚀🚀 ​ 🚀 Strong Buy Recommendation: Newron Pharmaceuticals S.p.A. (ISIN: IT0004147952) The stock of Newron Pharmaceuticals is recommended as a Highly Speculative Buy. This recommendation is driven by the unique, blockbuster potential of its lead candidate, Evenamide, in treating Treatment-Resistant Schizophrenia (TRS), …

Schedule III and the Chamber of Potions: The FDA Begins Advanced Herbology Congress could order the DEA to drop cannabis from Schedule I on a 90-day clock, triggering an FDA review of its medical use and opening the door for insurance-covered access through hospitals and major pharmacies supplied by operators …

[SCAM ALERT PART 2] KAY CAPITALS (SOMESH KAY) EXPOSED I. The Illusion of Mentorship I joined Kay Capitals University (KCU) when there were fewer than 10 students. It wasn’t a Discord empire yet, it was just Somesh, a few Zoom calls, and a lot of talk about “changing your life.” …

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced a deeper collaboration with Verix, a leader in AI-powered commercial optimization technology for the life sciences sector. Citius Oncology's …

AI Memory Hardware, Pharma & Strategic Industries – Watchlist 2026 Back in July, I put together a post highlighting a group of asymmetric, trend-driven stocks that were largely overlooked at the time. Most of them have rallied hard since. Now I’m putting together a fresh set of under-the-radar ideas for …

what we're seeing is a general rotation out of scrip (superfluous, useless tech) to commodities (actual material goods). There's a literal zero sum game between these two entities. read these books: Capital I-III several times. You will then understand this epoch-old phenomena. prepare accordingly.

$TII Titan Mining – OTC uplister to NYSE today: This tiny zinc producer is suddenly a serious U.S. critical-minerals story $TII just uplisted from OTC today, hit $2.70 yesterday, and the ask side is basically empty up to $3. I’ve been digging into the company and the shift happening here …

We might be looking at a hidden price explosion: $CANF holds cancer data Big Pharma usually pays billions for The company has released several major scientific updates recently — yet almost none of them received the attention they deserve, especially the cancer-related news. • They have a fully documented complete …

Stop watching the banks. The real bomb is ticking in the "Shadows" (Private Credit Deep Dive) Hey everyone, You turn on the news, and they’re still obsessed with traditional banks. But while everyone is staring at the front door, the back door has been wide open for years. Let’s demystify …

$ADVB – Sub-$20M biotech about to kick off human trials for lung cancer liquid biopsy (trial start imminent)-November according to latest 10Q Sharing some DD on $ADVB for anyone into small-cap biotech plays with upcoming catalysts.Quick specs: * Market cap \~$15–20M * True free float only \~8–9M shares (most held …

KEEP SGBX UNTIL FRIDAY OR YOU’LL REGRET IT WHEN IT SOARS **^ CLARIFICATION: UNTIL FRIDAY AT MARKET CLOSE** Why? SGBX will be on **day 12** for RegSho as of 11/20 at market open, **but shorts are forced to cover past day 13**. What does this mean? THIS IS WHEN THE …

Newron Pharmaceuticals: Still under investors radar 🚀 Strong Buy Recommendation: Newron Pharmaceuticals S.p.A. (ISIN: IT0004147952) The stock of Newron Pharmaceuticals is recommended as a Highly Speculative Buy. This recommendation is driven by the unique, blockbuster potential of its lead candidate, Evenamide, in treating Treatment-Resistant Schizophrenia (TRS), and the massive valuation …

Newron Pharmaceuticals- Strong Buy Recommendation 🚀 Strong Buy Recommendation: Newron Pharmaceuticals S.p.A. (ISIN: IT0004147952) The stock of Newron Pharmaceuticals is recommended as a Highly Speculative Buy. This recommendation is driven by the unique, blockbuster potential of its lead candidate, Evenamide, in treating Treatment-Resistant Schizophrenia (TRS), and the massive valuation gap …

Example: Medical Cannabis Rescheduling Act of 2026 Medical Cannabis Rescheduling Act of 2025 SECTION 1. SHORT TITLE. This Act may be cited as the “Medical Cannabis Rescheduling Act of 2025.” SECTION 2. FINDINGS. Congress finds the following: 1. The U.S. Department of Health and Human Services has officially recommended moving …

Breaking: America has been banned from ranked queue after going 10000/50/0 in another war against civilians in sandals. This is the 4th war they have had a Bronze III performance in despite ranking Challenger.